Illinois Governor Shared GLP-1 Weight Loss Journey

Governor JB Pritzker disclosed using GLP-1 medication to manage health as Illinois tracks rising drug safety concerns.

Updated on Oct. 6, 2026 in Weight Loss

Gouache-painted illustration of a glass vial on a pedestal, representing the delicate balance of metabolic health and medication management. — Illinois Governor JB Pritzker disclosed using GLP-1 medication for weight management, sparking wider debate on state insurance coverage and safety standards for obesity treatments. AI Illustration. Upload story photo >

Live Poll

Should health insurance plans cover weight-loss medications for their members?

In September 2026, 61-year-old Illinois Governor JB Pritzker revealed he lost 80 pounds using GLP-1 medication. The disclosure follows a 2023 expansion of state insurance coverage for weight loss treatments that cost Illinois $147 million in fiscal year 2025.

Why it matters

The governors disclosure highlights the growing national use of GLP-1 receptor agonists, now taken by 11% of U.S. adults, to address obesity-related conditions. This shift necessitates clear management of medication access and potential side effects within the state.

Active surveillance from U.S. poison centers indicates a 1,500% increase in calls regarding weight loss drugs since 2019, with local Illinois centers reporting a doubling of calls in one year. These figures reflect a broader rise in GLP-1 use, which now impacts 11% of U.S. adults.

The players

JB Pritzker

The current Governor of Illinois who has publicly disclosed his use of GLP-1 medication.

Kwame Raoul

The Illinois Attorney General who has issued safety warnings regarding the use of unapproved GLP-1 versions.

The details

GLP-1 receptor agonists function by mimicking hormones that signal fullness and regulate blood sugar levels, making them effective for treating both type 2 diabetes and obesity. To manage safety, the Illinois state insurance program requires enrollees to participate in a lifestyle management program alongside medication use. Despite these programs, state authorities have issued warnings regarding unapproved versions of these drugs, which are priced at $1,027.51 for standard options like Ozempic.

2005: The FDA approved the first GLP-1 medication.
July 2023: Illinois expanded state health insurance coverage for weight loss drugs.
Spring 2024: Governor Pritzker began taking GLP-1 medication.
Fiscal year 2025: The state insurance expansion cost Illinois $147 million.
September 2026: Governor Pritzker publicly disclosed his weight loss.

Health Landscape

The 1,500% increase in U.S. poison center calls related to weight loss drugs since 2019 frames the public health risk associated with rapidly expanding access to GLP-1 therapies. This trend underscores the challenge of balancing medication access with safety in the evolving obesity treatment landscape.

If you are considering GLP-1 medication, discuss the risks of unapproved versions and the necessity of lifestyle management programs with your primary care physician. Be aware that coverage eligibility, such as in Illinois, may depend on enrollment in supervised health programs.

The takeaway

Weight loss medications represent a significant shift in managing metabolic health, yet they require careful medical oversight to avoid safety issues. Always consult your physician to determine if GLP-1 therapy is appropriate for your specific health needs and to confirm safe, approved access.